Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

29 Jul 2005 18:04

Torex Retail PLC29 July 2005 Torex Retail plc29 July 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Unconditional as to Acceptances As at 1.00 p.m. on 29 July 2005, valid acceptances had been received in respectof 24,777,251 XN Checkout Shares (representing approximately 89.19 per cent ofXN Checkout's issued share capital). Accordingly, the Board of Torex Retail plc("Torex Retail") announces that the offer (the "Offer") made by EvolutionSecurities Limited on behalf of Torex Retail for XN Checkout Holdings PLC ("XNCheckout") has been declared unconditional as to acceptances. The Offer remains conditional upon the admission to trading on AiM of the newTorex Shares issued as consideration under the Offer ("New Torex Shares")becoming effective. Application has therefore been made for the admission of 63,107,579 New TorexShares to trading on AiM and it is expected that these New Torex Shares will beadmitted to trading on AiM and that dealings in those shares will commence on 4August 2005, when it is also expected that the Offer will become whollyunconditional. Save for the holding of Christopher Moore (Chief Executive of Torex Retail andNon-Executive Chairman of XN Checkout) of 2,580,497 XN Checkout Shares, neitherTorex Retail nor any persons deemed to be acting in concert with it for thepurposes of the Offer owned any XN Checkout Shares (or rights over such shares)on 3 June 2005 (being the last dealing day prior to the commencement of theOffer period) nor has Torex Retail nor any person deemed to be acting in concertwith it for the purposes of the Offer acquired or agreed to acquire any XNCheckout Shares (or rights over such shares) during the Offer period other thanby way of acceptances of the Offer. On 10 June 2005, Torex Retail announced that irrevocable undertakings to acceptthe Offer had been received from XN Checkout Shareholders who, in aggregate,have an interest in 10,540,085 XN Checkout Shares. Valid acceptances have beenreceived in respect of 8,500,718 of these XN Checkout Shares (representingapproximately 30.60 per cent of XN Checkout's issued share capital) and theseare included in the total above. In respect of the balance of 2,039,367 XNCheckout Shares, the acceptance form has been received duly signed, but without,as yet, sufficient supporting documentation to treat it as a valid acceptanceand therefore has not been included in the total above. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal Offer document dated 8 July 2005 shall, unless thecontext requires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO
18th Oct 20177:00 amRNSDirectorate Change
11th Oct 20177:15 amRNSHardman Research: Dual revenue stream growth
28th Sep 20173:15 pmRNSUnaudited Interim Results
8th Sep 20177:00 amRNSNotice of Results
5th Sep 20173:52 pmRNSNotification Of Major Holdings
30th Aug 20175:15 pmRNSIssue of Equity
16th Aug 201712:22 pmRNSHolding(s) in Company
11th Aug 20173:45 pmRNSHolding(s) in Company
11th Aug 20173:37 pmRNSHolding(s) in Company
10th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20172:45 pmRNSHolding(s) in Company
10th Aug 20171:10 pmRNSHardman Research: CellRight transforming US growth
10th Aug 201710:10 amRNSHolding(s) in Company
9th Aug 20173:00 pmRNSHolding(s) in Company
9th Aug 20172:30 pmRNSDirector/PDMR Shareholding
8th Aug 20171:41 pmRNSResults of General Meeting and Total Voting Rights
21st Jul 20176:00 pmRNSCirc re.CellRight Acquisition
21st Jul 20178:05 amRNSSuccessful fundraising of £40 million
20th Jul 20176:03 pmRNSProposed Acquisition and Placing
30th Jun 201712:00 pmRNSResult of AGM
2nd Jun 20177:00 amRNSAnnual results for period ended 31 December 2016
31st May 201710:46 amRNSPotential Acquisition Update
19th May 201711:35 amRNSPotential Acquisition
3rd Apr 20177:00 amRNSIssue of Equity
13th Mar 20177:10 amRNSHardman Research: Addressing woundcare in the US
1st Mar 20177:00 amRNSInnovative Technology Contract Awarded
2nd Feb 20177:00 amRNSDermaPure® added to the Federal Supply Schedule
6th Jan 20177:00 amRNSDirectorate Change
9th Dec 20167:15 amRNSHardman Research: a/c change: Not simply 11/12ths
7th Dec 20161:04 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Dec 20167:00 amRNSDermaPure secures GPO agreement with Premier, Inc.
28th Nov 20167:05 amRNSOrthoPureT XT update
22nd Nov 20167:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.